Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

Patents, Washington, DC 20231.

PATENT

Practitioner's Docket No. MPI00-304P1RM 703-872-9306

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

June 9, 2004 Signature Simonnø Corriveau Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must Identify each submitted paper.

Submitted herewith:

-
3)
3)
•
3

Total

Pages (10 pages) (Including this cover sheet)

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED PATIENTRAL FAX CENTER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Rosana Kapeller-Liberman

Application No.:

09/905,301

Group No.:

N/A

Filed: For:

July 13, 2001

Examiner:

Moore, William

23430, A NOVEL HUMAN UBIQUITIN HYDROLASE FAMILY MEMBER AND **USES THEREFOR**

Mail Stop **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL

- 1. Transmitted herewith for this application is/are:
 - This Transmittal (2 pages);
 - Revocation of Prior Powers of Attorney and Appointment of New Power of Attorney (2 b.
 - Associate Power of Attorney with Appendix A (3 pages); Ç.
 - Change of Attorney Docket Number (1 page) d.
 - Limited Recognition Under 37 CFR §10.9(b) (1page). e.

STATUS

2. Applicant is other than a small entity.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail. as "Express Mail Post Office to Addressee" Mailing Label No.

TRANSMISSION X

transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: ___June 9, 2004

Simonne Corriveau

(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

FEE DEFICIENCY

- 3. If any additional extension and/or fee is required, charge Account No. 501668. If any additional fee for claims is required, charge Account No. 501668.
- 4. Correspondence Address
 Direct all future correspondence to:

Customer Number 30405 OR

Intellectual Property Department MILLENNIUM PHARMACEUTICALS, INC.

40 Landsdowne Street Cambridge, MA 02139

June 9, 2004

MILLENNIUM PHARMACEUTICALS, INC.

y gan

Limited Recognition Under 37 C.F.R. §10.9(b)

40 Landsdowne Street Cambridge, MA 02139 Telephone - 617-577-3522 Facsimile - 617-551-8820

2004



Practitioner's Docket No. MPI00-304P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Rosana Kapeller-Liberman

Application No.:

09/905,301

Group No.:

N/A

Filed:

July 13, 2001

Examiner:

Moore, William

For:

23430. A NOVEL HUMAN UBIQUITIN HYDROLASE FAMILY

MEMBER AND USES THEREFOR

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

REVOCATION OF PRIOR POWERS OF ATTORNEY AND APPOINTMENT OF NEW POWER OF ATTORNEY

Dear Sir:

MILLENNIUM PHARMACEUTICALS, INC., the Assignee of the entire right, title and interest in the above-identified application by virtue of the Assignment document filed with the United States Patent and Trademark Office on October 12, 2001, at Reel 012285, Frame 0842 hereby revokes all Powers of Attorney with respect to that application heretofore granted and appoints the below listed attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent Office connected therewith.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

TRANSMISSION

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail. as "Express Mail Post Office to Addressee"

Mailing Label No.:

transmitted by facsimile to the Patent and Trademark Office.

Signature Simonne Corriveau

June 9, 2004

(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

Scott A. Brown	Reg. No. 32,724
Ian R. Silverman	Reg. No. 37,443
Jean M. Silveri	Reg. No. 39,030
Allan N. Kutzenco	Reg. No. 38,945
Janice M. Klunder	Reg. No. 41,121
Karoline K.M. Shair	Reg. No. 44,332
Kerri Pollard Schray	Reg. No. 47,066
Tracy M. Sioussat	Reg. No. 50,609

all of Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, Massachusetts 02139, United States of America.

Please direct all future correspondence to:

Customer Number 30405

OR

Intellectual Property Group
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
Cambridge, MA 02139

and direct all telephone calls to Jean M. Silveri at 617-679-7336.

MILLENNIUM PHARMACEUTICALS, INC.

Ву: _	lan R. Silverne
Турес	Name: Ian R. Silverman
Title:	Associate General Counsel
Dated	: June 9, 2004

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Rosana Kapeller-Liberman.

Application No.:

09/905,301

Group No.:

N/A

Filed:

July 13, 2001

Examiner:

Moore, William

For:

23430, A NOVEL HUMAN UBIQUITIN HYDROLASE FAMILY MEMBER AND

USES THEREFOR

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

ASSOCIATE POWER OF ATTORNEY

Dear Sir:

The undersigned attorney has the power of attorney in the subject application. He hereby grants an associate power to:

Mario Cloutier

Millennium Pharmaceuticals, Inc.

40 Landsdowne Street

Cambridge, MA 02139

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

TRANSMISSION

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail. as "Express Mail Post Office to Addressee"

Mailing Label No.

図 transmitted by facsimile to the Patent and Trademark Office.

Signature

Simonne Corriveau

Date: June 9, 2004

(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

USSN: 09/905,301

As demonstrated by Appendix A (submitted herewith), Mario Cloutier has passed the Patent Bar Examination and has been granted limited recognition under 37 C.F.R. §10.9(b). Please continue to forward all written and telephonic communications to Jean M. Silveri at the address and telephone number listed below.

Entry of the remarks made herein is respectfully requested.

Res	pectfully	submi	tted
1100	POULLER	Det/1111	

June 9, 2004

MILLENNIUM PHARMACEUTICALS, INC.

Ian R. Silverman

Registration No. 37,443

40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-679-7336 Facsimile - 617-551-8820

Appendix A

BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATE PATENT AND TRADEMARK OFFICE

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Mario Cloutier is hereby given limited recognition under 37 CFR, 10.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: March 1, 2005

Harry I. Moatz

Director of Enrollment and Discipline

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Rosana Kapeller-Liberman		
Application No.:	09/905,301	Group No.:	N/A
Filed:	July 13, 2001	Examiner:	Moore, William
For:	23430, A NOVEL HUMAN UBIQUITIN HYDROLASE FAMILY MEMBER AND USES THEREFOR		

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CHANGE OF ATTORNEY DOCKET NUMBER

Dear Sir.

Please note that the Attorney Docket Number has been changed from 381552002400 to <u>MPI00-304P1RM</u>. Please reference <u>MPI00-304P1RM</u> on all future correspondence.

Respectfully submitted, June 9, 2004 MILLENNIUM PHARMACEUTICALS, INC. Mario Cloutier Limited Recognition Under 37 C.F.R. §10.9(b) 40 Landsdowne Street Cambridge, MA 02139 Telephone - 617-577-3522 Facsimile - 617-551-8820

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

		AILING		
	deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.			
	37 C.F.R. SECTION 1.8(a)		37 C.F.R. SECTION 1.10*	
	with sufficient postage as first class mail.		as "Express Mail Post Office to Addressee" Mailing Label No.	
_		NOISSIME		
×	transmitted by facsimile to the Patent and Trademan		mora du con	
		Signat		
_	,		nne Corriveau	
Date:	<u>June 9, 2004</u>		r neint name afficerson cartifying)	

*WARNING:Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(type or print name of person certifying)

(Page 1 of 1)

BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATE PATENT AND TRADEMARK OFFICE

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Mario Cloutier is hereby given limited recognition under 37 CFR, 10.9(b) as an employee of Millenium Pharmaceuticals to prepare and prosecute patent applications wherein Millenium Pharmaceuticals is the assignee of record of the entire interest in the invention claimed in the application. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Mario Cloutier ceases to lawfully reside in the United States, (ii) Mario Cloutier's employment with Millenium Pharmaceuticals ceases or is terminated, or (iii) Mario Cloutier ceases to remain or reside in the United States on an H-1 visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Expires: March 1, 2005

Harry I. Moatz

Director of Enrollment and Discipline